曲美他嗪治疗不稳定型心绞痛(UAP)的临床疗效

摘要

Objective To investigate the clinical efficacy of trimetazidine in the treatment of unstable angina pectoris(UAP).Methods 54 cases of UAP from June 2010 to June 2011 in our hospital were randomly divided into control group and the treatment group,the control group received conventional β 1-blockers,nitrates preparation slow-molecular-weight heparin,calcium antagonists,the treatment group based on the conventional treatment of the control group was given trimetazidine,the two groups were compared with patient outcomes.Results The angina treatment effects of the two groups of patients were 81.48％ and 92.59％,the ECG assessment results were 51.85％ and 74.07％ respectively,ischemic attack times,ischemic time as well as ischemic area of comparison all showed statistical significant differences(P ＜ 0.05).Conclusions On the basis of conventional treatment the plus of trimetazidine can better improve the patients' clinical symptoms of UAP,and has no serious adverse events in the course of treatment,the treatment is safe,effective and quite advanced among similar methods,worthy of clinic promotion and application.%目的 探讨曲美他嗪治疗不稳定型心绞痛(UAP)的临床疗效.方法 将我院2010年7月至2012年6月收治的54例不稳定型心绞痛(UAP)患者随机分为对照组和治疗组,对照组进行常规的β1-受体阻滞剂、硝酸盐制剂、低分子肝素、钙拮抗剂治疗,治疗组在对照组常规治疗的基础上加用曲美他嗪治疗,最后比较两组患者的治疗效果.结果 两组患者间心绞痛的治疗效果(81.48％,92.59％)、心电图评定结果(51.85％,74.07％)、缺血发作次数、缺血时间以及缺血面积等方面进行比较,差异有显著性(P＜0.05).结论 在常规治疗的基础上加用曲美他嗪可以更好的改善不稳定型心绞痛(UAP)患者的临床症状,而且治疗过程中无严重的不良反应,治疗安全有效,是在治疗不稳定型心绞痛(UAP)中比较先进的治疗方法,值得临床推广和应用.